今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

威胜控股股价强劲反弹 机构预计电网投资高增长将持续

香港 - 威胜控股（03393）今日午后股价强劲反弹，涨幅近5%，收报7.18港元，成交额1628.92万港元。市场人士认为，这波上涨主要受两大利好因素驱动：一是国内电网投资保持高增长态势，二是公司自身业务发展向好。

电网投资高增将持续

信达证券指出，根据国家电网预计，2024年电网建设投资总规模将超5000亿元，这将带动国内电力设备需求大幅增长。截至2024年3月，2024年电网工程投资累计完成额为766亿，同比增长14.7%，电网投资高增趋势得到进一步确认。

公司业务发展向好

威胜控股作为一家领先的电力设备供应商，其主要业务包括电力变压器、输电线路和电气设备等。近年来，公司积极拓展海外市场，并加大研发投入，产品技术水平不断提升，市场竞争力持续增强。

机构看好威胜控股未来发展

多家机构看好威胜控股未来发展前景，并给予“买入”或“增持”评级。信达证券预计，公司2024年和2025年盈利将分别增长20%和25%，目标价为9港元。

威胜控股股价有望继续上行

综合来看，在电网投资高增长和自身业务发展向好的双重利好驱动下，威胜控股股价有望继续上行。投资者可逢低关注。

注意： 以上新闻稿仅供参考，不构成投资建议。投资者应自行判断投资风险。